NYCBS Becomes the First Community Cancer Center in New York to Offer Galleri®, GRAIL’s Multi-Cancer Early Detection Blood Test
New York Cancer & Blood Specialists (NYCBS), one of the Nation’s leading oncology practices, today announced its partnership with GRAIL, Inc., a health care company whose mission is to detect cancer early when it can be cured, to offer Galleri®, GRAIL’s multi-cancer early detection blood test, as a complement to recommended single cancer screening tests. NYCBS will be the first community cancer center in New York to offer the Galleri test.
“This innovative technology detects cancer DNA fragments and their cancer-specific signals that otherwise asymptomatic early cancers shed into the blood,” said Jeff Vacirca, MD, CEO of NYCBS. “With our wealth of experience in preventive and compassionate care for those at risk of cancer and those who need treatment for malignancy, we can best utilize this test to improve the health of our communities.”
Galleri detects more than 50 types of cancer, most of which are not commonly screened for today. With a simple blood draw and advanced machine learning, the Galleri test provides insights that can determine where in the body the cancer is located with high accuracy. The prescription-only blood test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test is intended to be used in addition to, and not replace, other cancer screening tests.
“When cancer is detected early, the chances of surviving it are much greater. The challenge is that, until now, screening tools have been limited to individually looking for just five out of the more than 100 cancers,” said Josh Ofman, MD, MSHS, president and chief medical officer of GRAIL. “With the Galleri test, we are changing the cancer screening paradigm by vastly expanding the number of cancers we can detect early with a simple blood test that looks for a common signal shared by approximately 50 cancers and does so with great precision.”
The Galleri test results may lead to the diagnosis of cancer and its organ of origin in earlier stages, enhancing the possibility of cure. This Galleri test is available for individuals who are at higher risk for developing malignancy by virtue of age, family history, lifestyle, or exposure to known carcinogens, and is not intended to confirm or detect cancer in a patient who has symptoms. A positive test will guide the patient and physician towards further directed testing that helps in diagnosing an otherwise occult early cancer and enables earlier treatment that may be lifesaving.
NYCBS is accredited by the American College of Radiation (ACR), the National Committee for Quality Assurance (NCQA), and the National Accreditation Program for Breast Centers (NAPBC). The practice performs various screenings for all types of cancer including lung, breast, prostate, and colorectal.
About New York Cancer & Blood Specialists
New York Cancer & Blood Specialists (NYCBS) is a leading oncology practice in the New York Metropolitan area committed to providing world-class, patient-centered affordable care to patients with cancer and blood disorders in their own communities, close to family and friends. We have more than 30 locations and 35 hospital affiliations throughout Nassau and Suffolk counties in the Bronx, Manhattan, Queens, and Brooklyn. We offer a multidisciplinary and comprehensive approach to care that utilizes the most advanced imaging, state-of-the-art therapies, cutting-edge clinical trials, on-site pharmacies, and an in-house laboratory with a full range of pathology services. Advocating for and ensuring the health and well-being of our patients is and always will be our priority. For more information, visit www.nycancer.com.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL, LLC, is a wholly-owned subsidiary of Illumina, Inc. (NASDAQ:ILMN).
For more information, please visit www.grail.com.
About Galleri®
The earlier that cancer is detected, the higher the chance of successful outcomes. The Galleri multi-cancer early detection test can detect more than 50 types of cancer, as defined by the American Joint Committee on Cancer Staging Manual, through a routine blood draw. When a cancer signal is detected, the Galleri test predicts the cancer signal origin, or where the cancer is located in the body, with high accuracy to help guide the next steps to diagnosis. The Galleri test requires a prescription from a licensed health care provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. It is intended for use in people with an elevated risk of cancer, such as those aged 50 or older.
For more information about Galleri, visit www.galleri.com.
Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “Cancer Signal Not Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory/Test Information
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the U.S. Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.